Kalbhen C L, Yetter E M, Olson M C, Posniak H V, Aranha G V
Stritch School of Medicine, Cardinal Bernadin Cancer Center, Loyola University Medical Center, Maywood, IL 60153, USA.
AJR Am J Roentgenol. 1998 Dec;171(6):1571-6. doi: 10.2214/ajr.171.6.9843290.
The purpose of this study was to determine the value of reinterpreting abdominal CT performed at other institutions when assessing the resectability of pancreatic carcinoma.
Fifty-three patients (30 men, 23 women; mean age, 62 years) referred to our tertiary care institution with newly diagnosed pancreatic carcinoma had formally reinterpreted abdominal CT scans and available initial reports. CT was performed at community hospitals (n = 47), university hospitals (n = 4), an outpatient clinic (n = 1), and an imaging center (n = 1); reinterpretation was performed by university radiologists with subspecialty expertise in abdominal imaging. On the basis of the initial and reinterpretation reports, the patients were categorized as having resectable or nonresectable disease. Medicare reimbursement rates were assessed.
The initial and reinterpretation reports agreed in 36 (68%) of the 53 patients, with the disease of 16 patients considered resectable and 20 unresectable by both reports. In 17 patients (32%), we found discrepancies between the initial and the reinterpretation reports. All discrepancies involved the initial report indicating resectability and the reinterpretation report consistent with nonresectable disease. Discrepancies were resolved by findings at surgery (n = 9), percutaneous biopsy (n = 3), dedicated pancreatic CT (n = 3), dedicated liver CT (n = 1), and follow-up abdominal CT (n = 1); the reinterpretation reports were correct in 16 (94%) of 17 patients. Reimbursement for outside CT reinterpretation, repeated abdominal CT, and an exploratory laparotomy were estimated at $46.45, $414.47, and $16,996.44, respectively.
Reinterpretation of outside abdominal CT was valuable for determining pancreatic carcinoma resectability and inexpensive when compared with repeating the CT examination or performing an exploratory laparotomy.
本研究旨在确定在评估胰腺癌可切除性时,重新解读在其他机构进行的腹部CT的价值。
53例新诊断为胰腺癌并转诊至我们三级医疗机构的患者(30例男性,23例女性;平均年龄62岁),其腹部CT扫描结果经过正式重新解读且有初始报告可用。CT检查在社区医院(n = 47)、大学医院(n = 4)、门诊诊所(n = 1)和影像中心(n = 1)进行;重新解读由在腹部影像方面有亚专业专长的大学放射科医生进行。根据初始报告和重新解读报告,将患者分类为可切除或不可切除疾病。评估了医疗保险报销率。
53例患者中有36例(68%)的初始报告和重新解读报告一致,两份报告均认为16例患者的疾病可切除,20例不可切除。17例患者(32%)的初始报告和重新解读报告存在差异。所有差异均涉及初始报告表明可切除,而重新解读报告认为不可切除。差异通过手术结果(n = 9)、经皮活检(n = 3)、专门的胰腺CT(n = 3)、专门的肝脏CT(n = 1)和腹部CT随访(n = 1)得以解决;17例患者中有16例(94%)的重新解读报告正确。外部CT重新解读、重复腹部CT和探查性剖腹手术的报销费用估计分别为46.45美元、414.47美元和16,996.44美元。
与重复CT检查或进行探查性剖腹手术相比,重新解读外部腹部CT对于确定胰腺癌可切除性具有重要价值且成本低廉。